Get the Stockscreener App
64.14
0.05%
-0.00
Hologic Inc stock is traded at $64.14, with a volume of 1.26M.
It is down -0.05% in the last 24 hours and up +12.89% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$64.14
Open:
$64.3
24h Volume:
1.26M
Relative Volume:
0.36
Market Cap:
$14.52B
Revenue:
$4.03B
Net Income/Loss:
$556.70M
P/E Ratio:
27.06
EPS:
2.37
Net Cash Flow:
$970.10M
1W Performance:
-0.73%
1M Performance:
+12.89%
6M Performance:
-10.30%
1Y Performance:
-10.30%
1-Day Range:
$63.76
$64.92
1-Week Range:
$63.76
$65.50
52-Week Range:
$51.90
$84.67
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
64.17 | 14.52B | 4.03B | 556.70M | 970.10M | 2.37 |
|
ISRG
Intuitive Surgical Inc
|
510.78 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
169.05 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
84.89 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
250.94 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
218.37 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Hologic Joins NEST Governance Committee - Medical Product Outsourcing
From Now to 2032: Unpacking the Bone Mineral Densitometry - openPR.com
Global C-Arms Market Trends & Forecast 2025-2032 | Major - openPR.com
Hologic (HOLX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Breast Cancer Diagnostics Market OutlookImaging, Biopsy & - openPR.com
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence? - Yahoo Finance
Is Hologic (NASDAQ:HOLX) Using Too Much Debt? - simplywall.st
BioZorb Lawsuit LawyerBreast Biopsy Marker RecallJune 2025 Update - Levin Papantonio
Bone Mineral Testing Market Generated Opportunities, Future - openPR.com
Tomosynthesis Market Set to Witness High Growth with Adoption of 3D Breast Imaging | Hologic Inc., GE Healthcare - openPR.com
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate? - The Globe and Mail
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact? - MSN
Can Hologic Lean On Its Strengths In A Tough Macroeconomic Climate? - Barchart.com
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know - Yahoo Finance
CGH and Hologic ink MoU on breast imaging research and education - MSN
Hologic Climbs 13% In A Month: How Should You Play The Stock? - Barchart.com
Hologic Climbs 13% in a Month: How Should You Play the Stock? - The Globe and Mail
Breast Cancer Diagnostic Market Set to Witness Advances in Imaging and Biomarkers | Hologic, GE Healthcare - openPR.com
Parallel Advisors LLC Has $60,000 Position in Hologic, Inc. (NASDAQ:HOLX) - Defense World
Uterine Fibroid Treatment Devices Market Set to Witness - openPR.com
Histology And Cytology Market Is Booming So Rapidly 2025-2032 - openPR.com
BNP Paribas Exane Adjusts Price Target on Hologic to $73 From $71, Maintains Outperform Rating - marketscreener.com
Clinical Laboratory Molecular Diagnostics for Infectious Disease Market Research 2025-2029: Biotechnology and Genomics Drive Advancements, Impact of Multiplex Assays in Diagnosis and Treatment - GlobeNewswire Inc.
BioZorb Lawsuit and Settlement Information: June 2025 - AboutLawsuits.com
Hologic at Jefferies Global Healthcare Conference: Strategic Insights - Investing.com
Hologic at Jefferies Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com UK
Transcript : Hologic, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-05-2025 11 - marketscreener.com
Gynecological Devices Market Set to Witness Significant Growth - openPR.com
Hologic at 45th Annual William Blair Growth Stock Conference: Strategic Focus on Women’s Health By Investing.com - Investing.com South Africa
Hologic at 45th Annual William Blair Growth Stock Conference: Strategic Focus on Women’s Health - Investing.com Australia
Hologic, Inc. (NASDAQ:HOLX) Short Interest Up 35.7% in May - Defense World
Hologic turns down $16 billion buyout offer from TPG and Blackstone - DOTmed
Breast Lesion Localization Methods Market Set to Witness Demand - openPR.com
Bone Densitometers Market Generated Opportunities, Future - openPR.com
Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation - Business Wire
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock - sharewise
X-ray Machine Manufacturing Market Is Booming Worldwide | - openPR.com
Digital X-ray Devices Market Is Booming So Rapidly 2025-2032Hologic, Inc., Hitachi, Ltd., Siemens Healthineers - openPR.com
Hologic turns down USD 16.7B non-binding offer from TPG, Blackstone - Medical Buyer
Blackstone (NYSE:BX) and TPG Eye US$16 Billion Hologic Buyout in Rejected Offer - simplywall.st
Hologic is reportedly a private equity takeover target - MassDevice
Hologic (HOLX) Surges 23% After Trade Resumption | HOLX Stock Ne - GuruFocus
TPG and Blackstone offer $16bn to take Hologic private in major healthcare bid - Private Equity Insights
Global markets live: Nvidia, General Motors, Hologic, Chevron, Stellantis… - marketscreener.com
Forecasting The Future: 6 Analyst Projections For Hologic - Benzinga
Needham Reiterates Hold Rating for Hologic (HOLX) | HOLX Stock N - GuruFocus
Q1 Earnings Outperformers: Hologic (NASDAQ:HOLX) And The Rest Of The Medical Devices & SuppliesImaging, Diagnostics Stocks - Yahoo Finance
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Hologic Inc Stock (HOLX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mitchell Essex D | Chief Operating Officer |
Dec 04 '24 |
Option Exercise |
62.60 |
22,902 |
1,433,659 |
52,813 |
| Mitchell Essex D | Chief Operating Officer |
Dec 04 '24 |
Sale |
76.34 |
24,856 |
1,897,482 |
27,957 |
0.13%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):